It has been said that the diagnosis of Alzheimer's disease enters the era of biomarkers. These two biomarkers, amyloids, and taus, defines Alzheimer's disease. In this presentation, Dr. Kai Wang, Senior Director of Biomarker Services at Frontage Laboratories, Inc, focuses on highly sensitive protein biomarker assays developed and validated at a testing laboratory and their application for the diagnosis of Alzheimer's disease.
Register to gain access to gated resources.
Thank you for registering!
You may now view the resource below.
Frontage has developed a next-generation sequencing (NGS)-based method to rapidly determine the genotype of 300+ genes involved in ADME, called the Frontage PGx NGS Test.
In this study, we quantify Neurofilament Light Chain (NF-L) in human plasma, serum, and CSF on the Quanterix Simoa™ Platform using a commercial Simoa NF-Light Assay Kit provided by Quanterix Corporation. We also discuss potential applications.
The human gut microbiome contains a complex aggregate of colonic bacterial enzymes mediating the metabolism of a wide range of xenobiotics and dietary components. This webinar highlights examples of pre-systematic drug clearance mediated by colonic enzymes contributing to systemic metabolite exposure, examines evidence of a causative link between dysbiosis and metabolic disorders, and concludes with an overview of established gut microbiome biomarkers and assay panels available to support investigations in understanding the metabolic fate of xenobiotics and colonic bacterial secondary metabolites.